Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gideon M Blumenthal

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Nature Reviews. Clinical Oncology|February 21, 2017
Approvals in 2016: the march of the checkpoint inhibitorsGideon M Blumenthal, Richard Pazdur
Nature Reviews. Clinical Oncology|February 1, 2018
Approvals in 2017: gene therapies and site-agnostic indicationsGideon M Blumenthal, Richard Pazdur
JAMA Oncology|February 26, 2016
Response Rate as an Approval End Point in Oncology: Back to the FutureGideon M Blumenthal, Richard Pazdur
Nature Reviews. Clinical Oncology|January 24, 2019
Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time reviewGideon M Blumenthal, Richard Pazdur
European Journal of Human Genetics : EJHG|September 11, 2008
PTEN hamartoma tumor syndromesGideon M Blumenthal, Phillip A Dennis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Germline PTEN mutations as a cause of early-onset endometrial cancerGideon M Blumenthal, Phillip A Dennis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2018
Leveraging the Success of HIV Drug Development Paradigms for CancerGideon M Blumenthal, Debra Birnkrant, Richard Pazdur
JAMA Oncology|November 28, 2019
Application of the Lung Immune Prognostic Index From Research to Clinical Practice-ReplyDickran Kazandjian, Yutao Gong, Gideon M Blumenthal
Journal of the National Cancer Institute|October 24, 2017
Real-world Data for Clinical Evidence Generation in OncologySean Khozin, Gideon M Blumenthal, Richard Pazdur
JAMA Oncology|November 6, 2015
Next-Generation Sequencing in Oncology in the Era of Precision MedicineGideon M Blumenthal, Elizabeth Mansfield, Richard Pazdur
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Nature Reviews. Clinical Oncology|February 21, 2017
Approvals in 2016: the march of the checkpoint inhibitorsGideon M Blumenthal, Richard Pazdur
Nature Reviews. Clinical Oncology|February 1, 2018
Approvals in 2017: gene therapies and site-agnostic indicationsGideon M Blumenthal, Richard Pazdur
JAMA Oncology|February 26, 2016
Response Rate as an Approval End Point in Oncology: Back to the FutureGideon M Blumenthal, Richard Pazdur
Nature Reviews. Clinical Oncology|January 24, 2019
Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time reviewGideon M Blumenthal, Richard Pazdur
European Journal of Human Genetics : EJHG|September 11, 2008
PTEN hamartoma tumor syndromesGideon M Blumenthal, Phillip A Dennis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Germline PTEN mutations as a cause of early-onset endometrial cancerGideon M Blumenthal, Phillip A Dennis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2018
Leveraging the Success of HIV Drug Development Paradigms for CancerGideon M Blumenthal, Debra Birnkrant, Richard Pazdur
JAMA Oncology|November 28, 2019
Application of the Lung Immune Prognostic Index From Research to Clinical Practice-ReplyDickran Kazandjian, Yutao Gong, Gideon M Blumenthal
Journal of the National Cancer Institute|October 24, 2017
Real-world Data for Clinical Evidence Generation in OncologySean Khozin, Gideon M Blumenthal, Richard Pazdur
JAMA Oncology|November 6, 2015
Next-Generation Sequencing in Oncology in the Era of Precision MedicineGideon M Blumenthal, Elizabeth Mansfield, Richard Pazdur
Pageof 9